普爱医疗等2家企业完成境外上市备案

Group 1: Core Insights - The China Securities Regulatory Commission has confirmed the overseas listing applications for Puhui Medical and Baoji Pharmaceutical, both aiming for a listing in Hong Kong [1] Group 2: Puhui Medical - Puhui Medical plans to issue no more than 34,500,000 overseas listed ordinary shares and list on the Hong Kong Stock Exchange [2] - The company submitted its prospectus to the Hong Kong Stock Exchange on April 30, but the prospectus has since expired. Puhui Medical specializes in the research, production, and sales of medical X-ray imaging equipment and orthopedic surgical robots, covering over 100 products across nine major series [4] - Financially, Puhui Medical reported revenues of 377 million yuan, 501 million yuan, and 484 million yuan for the fiscal years 2022 to 2024, with corresponding net losses of 43.7 million yuan, 15.97 million yuan, and 44.23 million yuan [5] Group 3: Baoji Pharmaceutical - Baoji Pharmaceutical plans to issue no more than 110,426,740 overseas listed ordinary shares and list on the Hong Kong Stock Exchange [6] - The company submitted its prospectus to the Hong Kong Stock Exchange on August 21, having previously submitted an application on January 21, 2025. Baoji Pharmaceutical is a clinical-stage biotechnology company focused on addressing complex diseases with limited treatment options. As of August 2025, it has seven clinical-stage candidates, including three core products, and holds nine authorized patents along with ten patent applications [8] - In terms of financial performance, Baoji Pharmaceutical reported revenues of 6.93 million yuan, 6.16 million yuan, and 4.20 million yuan for 2023, 2024, and the first six months of 2025, with corresponding net losses of 160 million yuan, 364 million yuan, and 183 million yuan [8]